ATGen Co.

Seongnam, South Korea

ATGen Co.

Seongnam, South Korea
SEARCH FILTERS
Time filter
Source Type

The present invention relates to an antibody that recognizes a specific motif of WLS protein so as to inhibit overactivation of the Wnt signaling pathway to thereby prevent or treat a disease associated with the Wnt signaling pathway, and to a pharmaceutical composition containing the same.


Jang S.,Yonsei University | Su H.,Yonsei University | Blum F.C.,Uniformed Services University of the Health Sciences | Bae S.,Yonsei University | And 14 more authors.
mBio | Year: 2017

Infection with Helicobacter pylori is a major risk factor for development of gastric disease, including gastric cancer. Patients infected with H. pylori strains that express CagA are at even greater risk of gastric carcinoma. Given the importance of CagA, this report describes a new molecular mechanism by which the cagA copy number dynamically expands and contracts in H. pylori. Analysis of strain PMSS1 revealed a heterogeneous population in terms of numbers of cagA copies; strains carried from zero to four copies of cagA that were arranged as direct repeats within the chromosome. Each of the multiple copies of cagA was expressed and encoded functional CagA; strains with more cagA repeats exhibited higher levels of CagA expression and increased levels of delivery and phosphorylation of CagA within host cells. This concomitantly resulted in more virulent phenotypes as measured by cell elongation and interleukin-8 (IL-8) induction. Sequence analysis of the repeat region revealed three cagA homologous areas (CHAs) within the cagA repeats. Of these, CHA-ud flanked each of the cagA copies and is likely important for the dynamic variation of cagA copy numbers. Analysis of a large panel of clinical isolates showed that 7.5% of H. pylori strains isolated in the United States harbored multiple cagA repeats, while none of the tested Korean isolates carried more than one copy of cagA. Finally, H. pylori strains carrying multiple cagA copies were differentially associated with gastric disease. Thus, the dynamic expansion and contraction of cagA copy numbers may serve as a novel mechanism by which H. pylori modulates gastric disease development. IMPORTANCE: Severity of H. pylori-associated disease is directly associated with carriage of the CagA toxin. Though the sequences of the CagA protein can differ across strains, previous analyses showed that virtually all H. pylori strains carry one or no copies of cagA. This study showed that H. pylori can carry multiple tandem copies of cagA that can change dynamically. Isolates harboring more cagA copies produced more CagA, thus enhancing toxicity to host cells. Analysis of 314 H. pylori clinical strains isolated from patients in South Korea and the United States showed that 7.5% of clinical strains in the United States carried multiple cagA copies whereas none of the South Korean strains did. This study demonstrated a novel molecular mechanism by which H. pylori dynamically modulates cagA copy number, which affects CagA expression and activity and may impact downstream development of gastric disease. IMPORTANCE Severity of H. pylori-associated disease is directly associated with carriage of the CagA toxin. Though the sequences of the CagA protein can differ across strains, previous analyses showed that virtually all H. pylori strains carry one or no copies of cagA. This study showed that H. pylori can carry multiple tandem copies of cagA that can change dynamically. Isolates harboring more cagA copies produced more CagA, thus enhancing toxicity to host cells. Analysis of 314 H. pylori clinical strains isolated from patients in South Korea and the United States showed that 7.5% of clinical strains in the United States carried multiple cagA copies whereas none of the South Korean strains did. This study demonstrated a novel molecular mechanism by which H. pylori dynamically modulates cagA copy number, which affects CagA expression and activity and may impact downstream development of gastric disease. © 2017 Jang et al.


Lee S.-B.,Yonsei University | Cha J.,ATGen Co. | Kim I.-K.,Yonsei University | Yoon J.C.,Ewha Womans University | And 9 more authors.
Biochemical and Biophysical Research Communications | Year: 2014

Natural killer (NK) cells are lymphocytes of the innate immune system and have the ability to kill tumor cells and virus-infected cells without prior sensitization. Malignant tumors and viruses have developed, however, strategies to suppress NK cells to escape from their responses. Thus, the evaluation of NK cell activity (NKA) could be invaluable to estimate the status and the outcome of cancers, viral infections, and immune-mediated diseases. Established methods that measure NKA, such as 51Cr release assay and CD107a degranulation assay, may be used to determine NK cell function, but they are complicated and time-consuming because they require isolation of peripheral blood mononuclear cells (PBMC) or NK cells. In some cases these assays require hazardous material such as radioactive isotopes. To overcome these difficulties, we developed a simple assay that uses whole blood instead of PBMC or isolated NK cells. This novel assay is suitable for high-throughput screening and the monitoring of diseases, because it employs serum of ex vivo stimulated whole blood to detect interferon (IFN)-γ secreted from NK cells as an indicator of NKA. After the stimulation of NK cells, the determination of IFNγ concentration in serum samples by enzyme-linked immunosorbent assay (ELISA) provided a swift, uncomplicated, and high-throughput assay of NKA ex vivo. The NKA results microsatellite stable (MSS) colorectal cancer patients was showed significantly lower NKA, 263.6±54.5pg/mL compared with healthy subjects, 867.5±50.2pg/mL (p value <0.0001). Therefore, the NKA could be utilized as a supportive diagnostic marker for microsatellite stable (MSS) colorectal cancer. © 2014 Elsevier Inc.


PubMed | Yonsei University, Ewha Womans University and ATGen Co.
Type: Journal Article | Journal: Biochemical and biophysical research communications | Year: 2014

Natural killer (NK) cells are lymphocytes of the innate immune system and have the ability to kill tumor cells and virus-infected cells without prior sensitization. Malignant tumors and viruses have developed, however, strategies to suppress NK cells to escape from their responses. Thus, the evaluation of NK cell activity (NKA) could be invaluable to estimate the status and the outcome of cancers, viral infections, and immune-mediated diseases. Established methods that measure NKA, such as (51)Cr release assay and CD107a degranulation assay, may be used to determine NK cell function, but they are complicated and time-consuming because they require isolation of peripheral blood mononuclear cells (PBMC) or NK cells. In some cases these assays require hazardous material such as radioactive isotopes. To overcome these difficulties, we developed a simple assay that uses whole blood instead of PBMC or isolated NK cells. This novel assay is suitable for high-throughput screening and the monitoring of diseases, because it employs serum of ex vivo stimulated whole blood to detect interferon (IFN)- secreted from NK cells as an indicator of NKA. After the stimulation of NK cells, the determination of IFN concentration in serum samples by enzyme-linked immunosorbent assay (ELISA) provided a swift, uncomplicated, and high-throughput assay of NKA ex vivo. The NKA results microsatellite stable (MSS) colorectal cancer patients was showed significantly lower NKA, 263.6 54.5 pg/mL compared with healthy subjects, 867.5 50.2 pg/mL (p value <0.0001). Therefore, the NKA could be utilized as a supportive diagnostic marker for microsatellite stable (MSS) colorectal cancer.


PubMed | Yonsei University, Korean International Vaccine Institute, Korea Research Institute of Bioscience and Biotechnology, ATgen Co. and Seoul National University
Type: Journal Article | Journal: Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology | Year: 2016

The pandemic strain of the influenza A virus (pH1N1) in 2009 caused many complications in patients. In this study, we introduce asthmatic symptoms as a complication of pH1N1 infection in children, not having a relationship with asthma history. The aim of this study was to quantify asthmatic symptoms in pH1N1-infected children and elucidate the underlying mechanisms of airway hyper-responsiveness (AHR) induced in a murine model of pH1N1 infection.As a retrospective study, pH1N1-infected children who were hospitalized with moderate to severe acute asthmatic symptoms were enrolled and administered a methacholine challenge test (MCT) at 3 months post-discharge. Additionally, the induction of AHR by pH1N1 infection was measured by MCT in wild-type and Rag1(-/-) mice. The effect of the innate immune response on the development of AHR following pH1N1 infection was investigated.More than 70% of the pH1N1-infected children without a pre-infection diagnosis of asthma had a negative response on the MCT. None of these children had recurrent wheezing or asthma during the 3 years following pH1N1 infection. The development of AHR in pH1N1-infected mice was associated with an elevation in IL-33 and innate lymphoid cells 2 (ILC2).This study demonstrates that pH1N1 infection directly induces transient asthmatic symptoms in patients regardless of their medical history. pH1N1 infection was shown to stimulate the rapid development of AHR and Th2-type cytokine secretion in mice via the activation of ILC2; it may be activated independently of adaptive immunity.


Bak E.J.,Yonsei University | Park H.G.,Atgc Biotechnology Co. | Lee C.,ATGen Co. | Lee T.-I.,ATGen Co. | And 4 more authors.
BMB Reports | Year: 2011

Chana series are new chalcone derivatives. To evaluate the possibility of Chana series as therapeutic agents of type 2 diabetes, the inhibitory effects of Chana series on the activities of α-glucosidase and DPP-4 were investigated using in vitro enzyme assays, and their effects on adipocyte differentiation were investigated in C3H10T1/2 cells. Chana 1 and Chana 7 among the Chana series showed significant inhibition of α-glucosidase activity. In DPP-4 enzyme assay, Chana 1 exhibited the highest inhibitory activity while Chana 7 did not. In MTT assay, Chana 1 did not show significant cytotoxicity up to a concentration of 250 μM, whereas cytotoxicity was observed with Chana 7 at a concentration of 300 μM. In addition, Chana 1 induced adipocyte differentiation. Therefore, Chana 1 showed inhibitory effects on α-glucosidase and DPP-4 as well as a stimulatory effect on adipocyte differentiation, suggesting that Chana 1 may be a potential beneficial agent for the treatment of type 2 diabetes.


Provided are a method for diagnosing cancer, a diagnosis kit and compositions useful for measurement of NK cell activity. The incidence of cancer may be diagnosed by monitoring changes in the in vivo immune system through measurement of NK cell activity in blood. Thus, the incidence of cancer may be readily predicted as described herein using a blood sample from a subject.


Trademark
ATGen Co. | Date: 2014-06-04

NK cell activation testing kits containing peptide substrates used in analyzing and detecting certain toxins for clinical, research or medical laboratory use; diagnostic kits for clinical laboratory use, namely, kits consisting primarily of monoclonal antibodies and/or recombinant proteins, RNA, DNA for use in disease diagnosis, screening, monitoring, prognosis, and immune status; diagnostic kits for medical laboratory use, namely, kits consisting primarily of monoclonal antibodies and/or recombinant proteins, RNA, DNA for use in disease diagnosis, screening, monitoring, prognosis, and immune status; diagnostic kits for medical research use, namely, kits consisting primarily of (monoclonal antibodies and/or recombinant proteins, RNA, DNA for use in disease diagnosis, screening, monitoring, prognosis, and immune status; diagnostic kits for clinical research use, namely, kits consisting primarily of monoclonal antibodies and/or recombinant proteins, RNA, DNA for use in disease diagnosis, screening, monitoring, prognosis, and immune status; diagnostic preparations for clinical laboratory use and medical laboratory use; diagnostic preparations for clinical research use other than for medical use; diagnostic reagents for clinical laboratory use, medical laboratory use, medical research use and clinical research use. diagnostic kits for medical diagnostic use, namely, kits consisting primarily of monoclonal antibodies and/or recombinant proteins, RNA, DNA for use in disease diagnosis, screening, monitoring, prognosis, and immune status; diagnostic activators in the nature of proteins for use in diagnostic kits for disease diagnosis, screening, monitoring, prognosis, and immune status; diagnostic preparations for medical diagnostic use; diagnostic reagents for medical diagnostic use.


Trademark
ATGen Co. | Date: 2013-11-28

(Based on Intent to Use) diagnostic preparations sold only as a component of a kit for clinical laboratory use and medical laboratory use; diagnostic preparations sold only as a component of a kit for clinical research use other than for medical use; diagnostic reagents sold only as a component of a kit for clinical laboratory use, medical laboratory use, medical research use and clinical research use. (Based on Intent to Use) diagnostic activators in the nature of a protein that activates immune cells for use in diagnostic kits that tests NK Cell activity.


Trademark
ATGen Co. | Date: 2014-06-04

proteins, neuroproteins, recombinant proteins, heat shock proteins, enzymes, ubiquitins, cancer related proteins, viral antigens, antibodies and hormones; diagnostic kits for clinical laboratory use, medical laboratory use, medical diagnostic use, medical research use and clinical research use; diagnostic activators for use in diagnostic kits; diagnostic preparations for clinical laboratory use, medical laboratory use, medical diagnostic use, medical research use and clinical research use; diagnostic reagents for clinical laboratory use, medical laboratory use, medical diagnostic use, medical research use and clinical research use. manufacture and supply of proteins, neuroproteins, recombinant proteins, heat shock proteins, enzymes, ubiquitins, cancer related proteins, viral antigens, antibodies and hormones; online sale of proteins, neuroproteins, recombinant proteins, heat shock proteins, enzymes, ubiquitins, cancer related proteins, viral antigens, antibodies and hormones; medical research services; clinical research services; research and development of medicines based on protein and peptide therapeutic applications; medical diagnostic services; manufacture and supply of in vitro diagnostic devices and antibody detection kits; custom medical services, namely, DNA cloning services, protein expression and purification services, monoclonal antibody services.

Loading ATGen Co. collaborators
Loading ATGen Co. collaborators